SCHEMBL4789914

SCHEMBL4789914

[AsH2]c1n[nH]cc1-c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 7/20 0.48
CYP3A4 P08684 4/20 0.48
ALDH1A1 P00352 3/20 0.48
CYP1A2 P05177 2/20 0.48
GSK3B P49841 1/20 0.46
DYRK1A Q13627 1/20 0.46
CYP2C9 P11712 2/20 0.45
CYP2B6 P20813 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP2E1 P05181 1/20 0.45
CYP2D6 P10635 1/20 0.45
PTGS2 P35354 1/20 0.44
METAP2 P50579 1/20 0.43
SIRT3 Q9NTG7 1/20 0.43
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924022 0.80 CYP2A6 (0.50) CYP2A6CYP3A4ALDH1A1CYP1A2GSK3B
SCHEMBL18292364 0.76 IDO1 (0.49) CYP2A6CYP3A4ALDH1A1CYP1A2GSK3B
SCHEMBL23329265 0.76 MKNK1 (0.49) CYP2A6CYP3A4ALDH1A1CYP1A2GSK3B
SCHEMBL30384675 0.75 METAP2 (0.47) CYP2A6CYP3A4ALDH1A1CYP1A2GSK3B
SCHEMBL28080860 0.75 CYP2A6 (0.44) CYP2A6CYP3A4ALDH1A1CYP1A2GSK3B
SCHEMBL17670258 0.75 METAP2 (0.47) CYP2A6CYP3A4ALDH1A1CYP1A2GSK3B
SCHEMBL952491 0.75 MKNK1 (0.50) CYP2A6CYP3A4ALDH1A1CYP1A2GSK3B
SCHEMBL7780720 0.74 PTGS2 (0.68) PTGS2
SCHEMBL28019369 0.71 DYRK1A (0.46) CYP2A6CYP3A4ALDH1A1CYP1A2GSK3B
SCHEMBL7772942 0.70 CA2 (0.62) GSK3BDYRK1APTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1993552-A2 USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS Novartis AG (CH) 2008-11-26 EP disclosed
WO-2007103432-A2 USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS NOVARTIS AG (CH) 2007-09-13 WO disclosed